Evidence map›Paper›PMID 37774317›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.

Patrick Y Wen, Martin van den Bent, Gilbert Youssef, Timothy F Cloughesy, Benjamin M Ellingson, Michael Weller, Evanthia Galanis, Daniel P Barboriak, John de Groot, Mark R Gilbert and 14 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06575452 (Using the Epitranscriptome to Diagnose and Treat Gliomas), which is not on this map. Cited by 391 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
391citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06575452 narecruitingnot on this mapstarted 2026, after this paper: background citation

Using the Epitranscriptome to Diagnose and Treat Gliomas

TypeinterventionalSponsorInstitut du Cancer de Montpellier - Val d'AurelleRan2026 to 2031Enrolled228ConditionsGliomaArmsBlood, urine and tumoral tissue samples, Tumoral tissue samples
3 · Its place in the literature

Who cites it

391 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Trial
  12. Vebreltinib for Previously Treated Astrocytoma,Cancer communications (London, England) · 2026
    Trial
  13. Image-based Re-evaluation of the JCOG0911 Study Focusing on Tumor Volume and Survival, Disease Progression Diagnosis, and Radiomic Prognostication for Newly Diagnosed Glioblastoma.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025
    Trial
  14. Dual Immune Check Point Blockade inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

331 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.ORCID 0000-0002-0774-7700
Martin van den BentDepartment Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.ORCID 0000-0001-5710-5127
Gilbert YoussefCenter for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.ORCID 0000-0001-6109-7692
Timothy F CloughesyUCLA Brain Tumor Program, Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.ORCID 0000-0002-8656-7483
Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.ORCID 0000-0002-2764-6640
Michael WellerDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.ORCID 0000-0002-1748-174X
Evanthia GalanisMayo Clinic, Department of Oncology, Rochester, MN.
Daniel P BarboriakDepartment of Radiology, Duke University Medical Center, Durham, NC.ORCID 0000-0002-2536-6266
John de GrootDivision of Neuro-Oncology, Department of Neurosurgery, University of California, San Francisco, CA.ORCID 0000-0003-1454-6461
Mark R GilbertNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Raymond HuangDivision of Neuro-radiology, Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0001-7661-797X
Andrew B LassmanDivision of Neuro-Oncology, Department of Neurology, Herbert Irving Comprehensive Cancer Center and Irving Institute for Clinical and Translational Research, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Hospital, New York, NY.ORCID 0000-0001-7386-9928
Minesh MehtaMiami Cancer Institute, Miami, FL.ORCID 0000-0002-4812-5713
Annette M MolinaroDivision of Biomedical Statistics and Informatics, Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-9854-7404
Matthias PreusserDepartment of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-3541-2315
Rifaquat RahmanDepartment of Radiation Oncology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0002-9443-1797
Lalitha K ShankarClinical Trials Branch, Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Roger StuppMalnati Brain Tumor Institute, Lurie Comprehensive Cancer Center and Departments of Neurological Surgery, Neurology and Division of Hematology/Oncology, Northwestern University, Chicago, IL.ORCID 0000-0002-5483-3118
Javier E Villanueva-MeyerDepartments of Radiology and Neurosurgery, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-5910-0757
Wolfgang WickDepartment of Neurology Heidelberg University Hospital & Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-6171-634X
David R MacdonaldDepartments of Clinical Neurological Sciences and Oncology (Emeritus), Western University, London, Ontario, Canada.
David A ReardonCenter for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.ORCID 0000-0001-6674-0157
Michael A VogelbaumDepartments of Neuro-Oncology and Neurosurgery, Moffitt Cancer Center, Tampa, FL.ORCID 0000-0002-9833-2374
Susan M ChangDivision of Neuro-Oncology, Department of Neurosurgery, University of California, San Francisco, CA.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastomaR01CA270027 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TIMOTHY CLOUGHESY, Benjamin M. Ellingson · 2022 to 2026
$3.0M
Quantitative molecular MR-PET imaging of glycolysis in glioblastomaR01CA279984 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Benjamin M. Ellingson, David A. Nathanson · 2023 to 2026
$2.4M
NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA270027NCI NIH HHS R01 CA279984
6 · The paper itself

Abstract

purposeThe Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some limitations of these criteria were identified, and challenges emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria.

methodsInformed by data from studies evaluating the different criteria, updates to the RANO criteria are proposed (RANO 2.0).

resultsWe recommend a standard set of criteria for both high- and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the postradiotherapy magnetic resonance imaging (MRI), rather than the postsurgical MRI, will be used as the baseline for comparison with subsequent scans. Since the incidence of pseudoprogression is high in the 12 weeks after radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, are required to define tumor progression. However, confirmation scans are not mandatory after this period nor for the evaluation of treatment for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (two-dimensional) but volumetric measurements are an option. For IDH wild-type glioblastoma, the nonenhancing disease will no longer be evaluated except when assessing response to antiangiogenic agents. In IDH-mutated tumors with a significant nonenhancing component, clinical trials may require evaluating both the enhancing and nonenhancing tumor components for response assessment.

conclusionThe revised RANO 2.0 criteria refine response assessment in gliomas.

Indexed as

Brain NeoplasmsGliomaAdultHumansMagnetic Resonance ImagingNeoplasm Recurrence, LocalReproducibility of Results

Identifiers

PMID37774317
PMCPMC10860967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.